Novartis AG / Kyorin Pharmaceutical Co., Ltd.

Chronic spontaneous urticaria (CSU) and mast cell-mediated diseases

1.4M US cases/yr · $4.8B Global CSU therapeutics market (2024 est) · ~50% Antihistamine-refractory CSU patient share

Disease Overview

Chronic spontaneous urticaria (CSU) is an immune-mediated skin disease defined by recurrent hives, angioedema, or both, occurring daily or almost daily for six weeks or longer without an identifiable external trigger. CSU affects approximately 1.4 million US adults at any given time, with a lifetime prevalence of around 1% of the general population and a 2-to-1 female predominance. Disease burden is substantial: patients report sleep disruption, work impairment, and quality-of-life decrements comparable to severe coronary artery disease. First-line therapy is second-generation H1-antihistamines at standard and then up-dosed (4x) doses, but roughly half of patients remain uncontrolled. Add-on omalizumab (Xolair, Genentech/Novartis), an anti-IgE monoclonal antibody, is the only FDA-approved biologic for antihistamine-refractory CSU, and approximately a third of patients do not achieve complete response. Remibrutinib (Novartis, BTK inhibitor) received FDA Priority Review for CSU in 2025. Beyond CSU, mast cell-mediated diseases span chronic inducible urticaria, atopic dermatitis with mast cell involvement, systemic mastocytosis, indolent mastocytosis, mast cell activation syndrome, and some forms of anaphylaxis. MRGPRX2 (Mas-Related G Protein-Coupled Receptor X2) is an emerging target expressed on mast cells that mediates IgE-independent degranulation and is implicated in pseudoallergic reactions, chronic urticaria, and drug-induced hypersensitivity — making it a pharmacologically novel axis for next-generation mast cell stabilization.

Competitive Landscape

The CSU competitive landscape centers on omalizumab (Xolair, Genentech/Novartis) as the incumbent biologic and now faces intensifying biologic and oral small-molecule competition. Novartis' own remibrutinib (a covalent BTK inhibitor) reported positive Phase 3 REMIX-1 and REMIX-2 data and received FDA filing in 2025, positioning it as the first oral advanced therapy for CSU. Celldex Therapeutics' barzolvolimab (anti-KIT mAb, mast cell depleting) is in Phase 3 for CSU and chronic inducible urticaria and is a leading next-generation biologic. Dupilumab (Dupixent, Regeneron/Sanofi) received FDA approval for CSU in April 2025 as an IL-4Ra antagonist adjunct. Emerging mechanisms include Jasper Therapeutics' briquilimab (anti-c-Kit), Incyte's povorcitinib (oral JAK1 inhibitor), and various Siglec-8 programs (Allakos lirentelimab, discontinued after failed Phase 3 in urticaria). MRGPRX2 antagonism is pharmacologically distinct from IgE-, BTK-, or c-Kit-directed strategies: it addresses the IgE-independent mast cell activation pathway implicated in drug-induced anaphylaxis and chronic urticaria. Kyorin's KRP-M223 is a preclinical oral MRGPRX2 antagonist that Novartis acquired ex-Japan rights to in this deal, complementing the Novartis mast cell portfolio alongside remibrutinib and Xolair.